The DG10S478 variant in the TCF7L2 gene is not associated with microvascular complications in type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 4, 2008, Pages 211-214

  Buchbinder, S ^a   Rudofsky Jr , G ^a   Humpert, P M ^a   Schilling, T ^a   Zorn, M ^a   Bierhaus, A ^a   Nawroth, P P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

DG10S478; Nephropathy; Neuropathy; Retinopathy; TCF7L2; Type 2 diabetes

Indexed keywords

TRANSCRIPTION FACTOR 7 LIKE 2;

ADULT; AGE; AGED; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; GENE INSERTION SEQUENCE; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PHYLOGENY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; TCF TRANSCRIPTION FACTORS; VARIATION (GENETICS);

EID: 42649123009     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993149     Document Type: Article

References (26)

1. Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S, Balkau B, Charpentier G, Pattou F, Stetsyuk V, Scharfmann R, Staels B, Frühbeck G, Froguel P. Transcription factor TCF7L2 genetic study in the French population. Expression in human β-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006; 55: 2903-2908
2. Couffinhal T, Dufourcq P, Duplaa C. Beta-catenin nuclear activation: common pathway between Wnt and growth factor signalling in vascular smooth muscle cell proliferation? Circ Res 2006; 99 (12): 1287-1289
3. Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD, Mitchell BD, Shuldiner AR. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish. Diabetes 2006; 55: 2654-2659
4. DCCT Research Group. Factors in the development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of diabetic control and complications trials. Diabetes 1988; 37: 471-481
5. Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R. The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 2000; 60: 3872-3879
6. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, Intruments & Computers: in press 2007
7. Florez JC, Jablonski KA, Bayley N, Pollin TI, Bakker PIW de, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. N Engl J Med 2006; 20: 241-250
8. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38: 320-323
9. Helgason A, Pálsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S, Adeyemo A, Chen Y, Chen G, Reynisdottir I, Benediktsson R, Hinney A, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Schäfer H, Faruque M, Doumatey A, Zhou J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Sigurdsson G, Hebebrand J, Pedersen O, Thorsteinsdottir U, Gulcher JR, Kong A, Rotimi C, Stefánsson K. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007; 39 (2): 218-225
10. Kiessling A, Ehrhart-Bornstein M. Transcription factor 7-like 2 (TCFL2) - a novel factor involved in pathogenesis of type 2 diabetes. Comment on: Grant et al. Nature Genetics 2006. Horm Metab Res 2006; 2: 137-138
11. Kim KI, Cho HJ, Hahn JY, Kim TY, Park KW, Koo BK, Shin CS, Kim CH, Oh BH, Lee MM, Park YB, Kim HS. Beta-catenin overexpression augments angiogenesis and skeletal muscle regeneration through dual mechanism of vascular endothelial growth factor-mediated endothelial cell proliferation and progenitor cell mobilization. Arterioscler Thromb Vasc Biol 2006; 26 (1): 91-98
12. Lehman DM, Hunt KJ, Leach RJ, Hamlington J, Arya R, Abboud HE, Duggirala R, Blangero J, Goring HH, Stern MP. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans. Diabetes 2007; 56: 389-393
13. Loos RJ, Franks PW, Francis RW, Barroso I, Gribble FM, Savage DB, Ong KK, O'Rahilly S, Wareham NJ. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007; 56: 1943-1947
14. Lynch M, Kewalramani A. Messenger RNA surveillance and the evolutionary proliferation of introns. Mol Biol Evol 2003; 20: 563-571
15. Marzi C, Huth C, Kolz M, Grallert H, Meisinger C, Wichmann HE, Rathmann W, Herder C, Illig T. Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res 2007; 39: 46-52
16. Miriami E, Sperling R, Sperling J, Motro U. Regulation of splicing: the importance of being translatable. RNA 2004; 10: 1-4
17. Oving IM, Clevers HC. Molecular causes of colon cancer. Eur J Clin Invest 2002; 32: 448-457
18. Parra EJ, Cameron E, Simmonds L, Valladares A, MacKeigue P, Shriver M, Wacher N, Kumate J, Kittles R, Cruz M. Association of TCF7L2 polymorphisms with type 2 diabetes in Mexico City. Clin Genet 2007; 71 (4): 359-366
19. Prunier C, Hocevar BA, Howe PH. Wnt signaling: physiology and pathology. Growth Factors 2004; 22: 141-150
20. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289: 950-953
21. Rudofsky Jr G, Isermann B, Schilling T, Schiekofer S, Andrassy M, Schneider JG, Morcos JM, Humpert PM, Sayed AA, Witte S, Renn W, Pfohl M, Hamann A, Nosikov V, Schleicher E, Haring HU, Rudofsky G, Ritz E, Nawroth PP, Bierhaus A. A 63 bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112: 135-141
22. Schäfer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, T'hart LM, Nijpels G, Haeften TW van, Häring HU, Fritsche A. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007, Jul 28; [Epub ahead of print]
23. Scott LJ, Bonnycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N, Duren WL, Chines PS, Stringham HM, Erdos MR, Valle TT, Tuomilehto J, Bergman RN, Mohlke KL, Collins FS, Boehnke M. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006; 55: 2649-2653
24. Smith U. TCF7L2 and type 2 diabetes-we WNT to know. Diabetologia 2007; 50: 5-7 Epub 2006 Nov
25. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005; 280: 1457-1464
26. Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, Dam RB van, Hu FB. Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S women and men. Diabetes 2006; 55: 2645-2648